Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Bale TA, Sait SF, Benhamida J, Ptashkin R, Haque S, Villafania L, et al. Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY). Acta Neuropathol. 2021;141(1):123-125.

DeSimone RA, Vinchi F. Screening out the Exposome to Improve Transfusion Quality. Hemasphere. 2021;5(7):e605.

Ma L, Zhao Z, Racine-Brzostek SE, Yang HS. A rare case of persistent pseudohypobicarbonatemia arising from chemistry analyzer-specific interference. Clin Chim Acta. 2021;519:308-310.

Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. bioRxiv. 2021.

Fontan L, Goldstein R, Casalena G, Durant M, Teater MR, Wilson J, et al. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood. 2021;137(6):788-800.

Racine-Brzostek SE, Karbaschi M, Gaebler C, Klasse PJ, Yee J, Caskey M, et al. TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. medRxiv. 2021.

Kasashima H, Duran A, Cid-Diaz T, Muta Y, Kinoshita H, Batlle E, et al. Mouse model of colorectal cancer: orthotopic co-implantation of tumor and stroma cells in cecum and rectum. STAR Protoc. 2021;2(1):100297.

Leo P, Chandramouli S, Farré X, Elliott R, Janowczyk A, Bera K, et al. Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2. Eur Urol Focus. 2021;7(4):722-732.

Chapel DB, Lee EK, Da Silva AF, Teschan N, Feltmate C, Matulonis UA, et al. Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. Mod Pathol. 2021;34(3):613-626.

Sun M, Schaap A, Robinson BD, Nanus DM, Tagawa ST. A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. Am J Clin Exp Urol. 2021;9(5):390-396.